Send to

Choose Destination
Circ Res. 2014 May 9;114(10):1564-8. doi: 10.1161/CIRCRESAHA.114.303720.

Bone marrow mononuclear cell therapy for acute myocardial infarction: a perspective from the cardiovascular cell therapy research network.

Author information

From Mayo Clinic, Rochester, MN (R.D.S., D.B.S.); University of Florida School of Medicine, Gainesville (C.J.P., R.D.A.); Minneapolis Heart Institute at Abbott Northwestern Hospital, University of Minnesota School of Medicine (J.H.T.); Cedars-Sinai Heart Institute, Los Angeles, CA (T.D.H.); University of Louisville School of Medicine, KY (R.B.); The University of Texas MD Anderson Cancer Center, Houston (E.Y.); University of Miami Miller School of Medicine, FL (J.M.H., I.H.S.); Florida Hospital Tampa Pepin Heart Institute (C.L.); University of Texas Health Science Center School of Public Health, Houston (S.L.S., L.A.M.); Texas Heart Institute, Houston (D.A.T.); and National Heart, Lung, and Blood Institute, Bethesda, MD (R.F.E.).


To understand the role of bone marrow mononuclear cells in the treatment of acute myocardial infarction, this overview offers a retrospective examination of strengths and limitations of 3 contemporaneous trials with attention to critical design features and provides an analysis of the combined data set and implications for future directions in cell therapy for acute myocardial infarction.


diagnostic imaging; myocardial infarction; population

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center